Related Experiment Videos
[Neutralizing human antibody specific for human cytomegalovirus in E. coli expression system]
S Ihara1, F Maeda, M Takekoshi
1Department of Molecular Life Science 2, Tokai University, School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 18, 1998
Summary
Researchers developed a human antibody fragment (Fab) that neutralizes human cytomegalovirus (HCMV). This specific Fab fragment targets late-stage viral proteins, offering a potential therapeutic strategy against HCMV infections.
Area of Science:
- Virology
- Immunology
- Biotechnology
Background:
- Human cytomegalovirus (HCMV) is a significant pathogen, particularly in immunocompromised individuals.
- Effective antiviral therapies targeting HCMV remain a critical unmet medical need.
- Neutralizing antibodies offer a promising avenue for antiviral intervention.
Purpose of the Study:
- To isolate and characterize novel human antibody fragments with neutralizing activity against HCMV.
- To identify specific viral targets recognized by these antibody fragments during infection.
Main Methods:
- Construction of phage display Fab libraries from healthy donor peripheral lymphocytes.
- Screening of libraries for reactivity against HCMV-infected cells.
- Characterization of antibody binding kinetics and neutralization capacity.
Main Results:
- Isolation of a specific human Fab fragment, designated 13-3, reactive to HCMV-infected cells.
- The 13-3 Fab fragment recognized viral proteins synthesized at late stages of HCMV infection.
- The 13-3 Fab fragment demonstrated efficient and specific neutralization of the HCMV Towne strain, with no activity against HSV-1 or HSV-2.
Conclusions:
- A novel human Fab fragment capable of neutralizing HCMV has been successfully isolated.
- This Fab fragment targets late-acting viral proteins, suggesting a specific mechanism of action.
- The 13-3 Fab fragment represents a potential candidate for developing targeted HCMV therapies.